The result showed that, compared with the control group and the lenvatinib monotherapy group, the combination of the knockdown ARHGEF2 with lenvatinib achieved better tumor inhibition in vivo (Fig. 6H–J). The gene discussed is ARHGEF2; the disease is neoplasm.